Phase 1/2 × Carcinoma, Merkel Cell × pembrolizumab × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
NCT03277352 2021-07-22

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Terminated
10 enrolled 14 charts